Myriad stock down on Sanofi drug failure; Angiotech files for protection during restructuring;

> Myriad Genetics, maker of a test to determine whether breast cancer patients can benefit from an experimental group of medicines, fell the most since May after the leading drug in that class failed in a study. Sanofi-Aventis reported last week that its drug, BSI- 201, failed to meet its primary goals of helping patients live longer with a difficult-to-treat type of breast cancer. News

> Troubled medical devicemaker Angiotech Pharmaceuticals says it has filed for court protection from creditors while it restructures and cuts its debts. Story

> Biomet and the Orthopaedic Research and Education Foundation (OREF) announced today Biomet's 2011 donation of $1.3 million for funding graduate medical education programs in orthopaedic surgery. This donation represents a continuation of Biomet's multi-year partnership with OREF to support training of orthopaedic residents and fellows. Biomet release

> State officials say Greatbatch Medical will move operations in Whitley County to Fort Wayne. The medical instrument and orthopedic product manufacturer says it will invest $17 million and create up to 76 jobs by 2014. Article

> Richard Mueller has been named chief technology officer at TransEnterix. TransEnterix release

> The Malaysian government should consider reviewing its outdated policies on condom and infant-related products and categorize them as medical devices. Takaso Resources Bhd managing director Francis Tee Tze Chern said Malaysia was the only country in the region that labelled them as consumer products and not medical devices. Item

> Varian Medical Systems has announced the execution of a three year, approximately $450 million contract for Varian to supply medical imaging subcomponents to Toshiba Medical Systems for integration into diagnostic imaging equipment for the global market. Orders will be booked over the period of the agreement. Varian release

> A federal appeals court partially overturned a lower court decision awarding a $2.7 million judgment to Medtronic (NYSE:MDT) in a patent spat over spinal stabilization technology with Globus Medical. Decision | Story

> Flatley Venture Capital, VC firm with a focus on cystic fibrosis, has launched, Mass High Tech reports. Flatley plans to offer capital ranging from $200,000 to $2 million to cystic fibrosis-focused biotechs and medical device firms, as well as lab space to companies in Boston and Nashua, NH, MHT reports. Article

And Finally... Corporate dealmakers are back in business. Big-time. Story